Women's Health

The comprehensive timeline highlights how WHI findings and subsequent research reshaped HRT risk assessment, guidance, and FDA labeling through 2025.

Access, cost, and clinician awareness remain significant barriers to implementing supplemental breast screening, according to Plecha.

Breast imaging expert Donna M. Plecha, MD, explains the FDA's dense breast notification requirement and when to recommend supplemental MRI screening.

Mitchell highlights hormone therapy prescribing for primary care: treatment algorithms, vaginal estrogen safety, and when progestins aren't needed.

TMS 2025: Katrina Wugalter, MA, discusses research showing that age—not menopause stage—drives brain volume decline, and how lifestyle factors can help preserve brain health in midlife women.

Regulatory update aims to align labeling with current evidence on menopausal hormone therapy safety and benefits

TMS 2025: Dr Marla Shapiro doesn't start perimenopausal therapy without an answer to the most important question: "What is your most bothersome symptom?"

Women experience greater CR mortality benefits than men yet have 36% lower enrollment. New AHA statement addresses barriers across the care continuum.

Lisa Larkin, MD, discusses how elinzanetant may change menopause management for women who can’t use hormone therapy and what PCPs need to know.

"If you don't know where your keys are, that's fine." Shapiro's memorable analogy helps distinguish perimenopause brain fog from serious cognitive concerns.

Genitourinary symptoms of menopause often are ignored--by patients and practitioners alike. Primary care clinicians are in a key position to identify, educate, and initiate treatment.

TMS 2025: Donna Plecha, MD, discusses how primary care physicians should approach breast cancer screening in women with dense breasts and use MRI effectively.

TMS 2025: Cochrane explains the impetus behind 2 studies she has authored on the patient- and provider-level factors that influence MHT prescribing.

New research from TMS 2025 covers menopause effects on brain volume, hormone therapy's role in weight loss with GLP-1s, and dense breast screening updates.

Early breast cancer screening at age 40, especially with 3D mammograms, significantly improves survival rates and quality of life, according to Dr Plecha.

Smoking drives lung cancer deaths, but race predicts breast/prostate mortality. New study reveals distinct community factors for each cancer type's outcomes.

Common questions on the critical window hypothesis for timing of postmenopausal MHT ask about rationale, clinical evidence, and guideline response.

Karim discusses secondary findings from the ELITE trial of timing for estradiol initiation, which reveal a notable impact on Aβ biomarkers of Alzheimer disease.

Menopause specialist Caroline Mitchell, MD, MPH, explains the dual nature of the breakdown in communication that can leave women virtually uninformed about GSM and treatment.

Jiang shares how to use new autoimmune risk data responsibly—identifying high-risk patients while avoiding unnecessary hormone therapy phobia.

Dr. Daniel Jiang shares unexpected research findings showing hormone therapy increased autoimmune disease risk across 15 of 17 conditions in postmenopausal women.

TMS 2025: Jiang explains why he investigated hormone therapy's effect on autoimmune disease risk in postmenopausal women.

The phase 3 E4COMFORT II trial found no impact on BP after 1 year of treatment in postmenopausal women with elevated HbA1c, lipids, and TGs.